" MedGenesis has advanced CED to a potentially disruptive platform technology with a broad range of applications. CED employs a local pressure gradient to infuse fluid (in this case containing the therapeutic GDNF) into the brain, allowing for up to a 1,000-fold increase in the distribution volume relative to conventional diffusion. The MedGenesis proprietary CED system allows for targeting of specific areas in the brain resulting in the accurate distribution of therapeutics.

This integrated approach provides for the potential of a safe, simple, and effective long-term treatment of patients with Parkinson’s disease on an out-patient basis. Patients will continue to see their neurologists monthly, where no more than 1-2 hours will be required to receive the non-invasive infusion that does not even require puncture with a needle."